Nothing Beats Free
Nanoporous cavities on strut abluminal surface functioning as drug carrier to ensure the firm adhesion.
Vacuum drug coating technology ensures complete drug dosage and coating stability.
Post-treatment after drug loading helps with sustained drug release.
Soft tapered tip provides smooth transition from guidewire to balloon catheter and excellent crossability.
Short shoulder design at both ends of the balloon ensures the accurate dilation to the lesion, and reduces the damage to normal vessel next to the lesion.
Patented hydrophilic coating on distal shaft provides outstanding pushability.
Polymer-free design significantly reduces the inflammatory response after stent implantation to guarantee the long-term safety.
Polymer-free design facilitates earlier endothelialization which significantly shorten the DAPT time.
The rough strut surface helps with earlier and easier endothelialization to reduce the risk of thrombosis.
DES Efficacy 
BMS Safety 
Nano+™ OCT Study
An OCT Study in Europe Shows Nano+™ A Great Combination of DES Efficacy and BMS Safety
Nanoporous drug carrier on abluminal surface
Balanced strut thickness
High radial force
Sine wave + 3-3-3 link
Double helix structure
Large open cell
Precise positioning markers
Effective drug of Sirolimus
Vacuum drug coating technology
90-day drug releasing period
New delivery system
Significantly shorten DAPT time
Earlier & better endothelialization
Highly reduced risk of thrombosis
Easy positioning and placement
Optimal tissue scaffolding
Excellent side branch access
Scientific drug releasing period
Ø 2.5 - 4.0 mm
12 - 36 mm multi stent lengths
An OCT Study in Europe Shows Nano+™ A Great Combination of DES Efficacy and BMS Safety .
In a prospective, multicentre, single-arm, open-label study, OCT examinations
were performed at three months in 45 patients (47 lesions). 23 patients with 24 lesions
had serial coronary angiography and OCT assessment at three and six months.
Coverage status of the individual stents/patients at two time points (three and six months).
Serial OCT showed almost complete vascular healing at six months, even when coverage was insufficient at three months. This suggests an adequate safety and efficacy profile of the device at that point in time.
|Stent Material||316L Stainless Steel|
|Strut Design||Nanoporous drug carrier on abluminal surface|
|Metal to Artery Ratio||15%|
|Stent Diameter||Stent Length (mm)|
Please contact us for detailed information in your country.
*Product registration and availability vary by country. For more information on product availability, please contact us here.